Breaking the “Undruggable” Barrier in EGFR Exon 20 Insertion+ NSCLC

Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC

June 3, 2026

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases

June 3, 2026

Sequential Erlotinib Plus Ramucirumab Prior to Osimertinib Fails to Improve Outcomes in EGFR L858R–Mutant NSCLC

June 1, 2026

Sunvozertinib Shows Superior Efficacy vs Chemo in Frontline Advanced EGFR Exon 20+ NSCLC

May 30, 2026